ICON plc | Clinical Research Organisation (CRO) for Drug Development

Webinar: A Novel Approach to ALS Trial Development

Review insights on ALS studies and recruitment challenges involving newly diagnosed rare disease participants.

Webinar: Successful Digital Trial Template

Explore the best practices for implementing a successful digital trial.

New Drug Safety Reporting Solution

Combining expertise, regulatory intelligence and automation for increased compliance.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

18 March 2019

Benefits of Implementing a Unified Patient Experience in Clinical Trials

Inconsistent patient engagement has been a leading challenge in clinical trials. Learn how to overcome this challenge and maximise your trial's potential today.

14 March 2019

A New Reality: EMA Published First Guidance on New MDR/IVDR Rules for Certain Devices

EMA recently published the first of a series of guidance documents to help applicants prepare for obligations enforced by new EU regulations on medical devices.

05 February 2019

ADDPLAN® neo Blog Series

Read about our latest version of the ADDPLAN® Platform, ADDPLAN® neo, a fully validated, stand-alone, fixed and adaptive design simulation and analysis tool.

05 February 2019

Regulatory Agencies Encourage Use of Adaptive Designs

Over the past few years, regulators (FDA, EMA & PMDA) have provided guidance on the use of adaptive design for clinical development. Learn more here.

05 February 2019

An Introduction to Applications of Adaptive Design: Avoiding Unnecessary Delays, Failures

Learn how the adoption of an adaptive design strategy across the product development process brings a number of important benefits in this blog.

05 February 2019

Adaptive MCP-Mod adds powerful dose-finding capabilities to ADDPLAN® neo

MCP-Mod can support the efficient identification of appropriate dose ranges for pivotal trials.

24 January 2019

Convergent Development

Convergent development is key to remaining competitive in the evolving healthcare landscape

11 January 2019

Clinical Safety Data Management - ICH E2B (R3)

In an increasingly globalised Pharmaceutical industry, harmonization is essential to assure the safety of patients.

07 January 2019

What is the Value of Real World Evidence in Oncology in HTA Appraisals?

ICON Pricing and Market Access experts conducted an analysis to assess the value of RWE in recent HTA appraisals.

Services

Therapeutics

Innovation

Insights

News & Events

About ICON

2019 CRO Leadership Awards

ICON Acquires MolecularMD

Making Sense of the Biosimilars Market

Personalising Digital Health